Sharp Moves Into Massachusetts With $28M Boost

Sharp Sterile Manufacturing invests $28M in Lee, MA, to boost sterile filling capacity for rare and orphan disease injectable therapies

29 Jun 2026

Sharp Sterile Manufacturing is investing $28m to expand sterile filling capacity at its facility in Lee, Massachusetts, targeting the market for injectable rare and orphan disease therapies. The expansion reflects a broader shift toward specialized domestic production in the contract development and manufacturing organization (CDMO) sector.

The investment will add production lines to serve small-to-medium scale biotechnology clients requiring specialized sterile manufacturing and established regulatory compliance. Local capacity expansion addresses tightening supply constraints for regional drug developers, who face logistical risks and extended lead times when relying on overseas partnerships.

"The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies," said Kevin Orfan, President and CEO of Sharp. Growing complexity in biopharmaceutical pipelines has placed pressure on contract manufacturers to scale operations quickly while maintaining rigorous quality standards.

Sharp Services, the parent organization, aims to strengthen its integrated capabilities by offering a wider range of services at a single site.

For patients with rare conditions, local capacity expansion can shorten the transition from clinical development to commercial supply. Because orphan drug programs typically operate with limited resources, efficient contract manufacturing is critical to avoiding market delays. The investment reflects an industry trend where dedicated capacity for underserved patient populations is becoming a primary competitive focus rather than a niche offering.